Healthcare provider profile · identity verified

Lisa Driscoll, MD

Internal Medicine · BOISE, ID · NPI 1427545805

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	440	129
Levothyroxine Sodium	Levothyroxine Sodium	427	120
Losartan Potassium	Losartan Potassium	262	76
Omeprazole	Omeprazole	224	66
Amlodipine Besylate	Amlodipine Besylate	223	60
Gabapentin	Gabapentin	174	55
Metoprolol Succinate	Metoprolol Succinate	149	43
Lisinopril	Lisinopril	142	43
Metformin Hcl	Metformin Hcl	114	32
Rosuvastatin Calcium	Rosuvastatin Calcium	113	35
Escitalopram Oxalate	Escitalopram Oxalate	111	28
Simvastatin	Simvastatin	108	28
Trazodone Hcl	Trazodone Hcl	99	33
Metformin Hcl Er	Metformin Hcl	92	28
Mounjaro	Tirzepatide	92	14
Furosemide	Furosemide	82	27
Pravastatin Sodium	Pravastatin Sodium	81	22
Spironolactone	Spironolactone	78	18
Eliquis	Apixaban	76	29
Famotidine	Famotidine	75	26
Hydrochlorothiazide	Hydrochlorothiazide	75	29
Alendronate Sodium	Alendronate Sodium	74	25
Albuterol Sulfate Hfa	Albuterol Sulfate	73	29
Carvedilol	Carvedilol	72	21
Bupropion Xl	Bupropion Hcl	68	19
Duloxetine Hcl	Duloxetine Hcl	68	19
Fluoxetine Hcl	Fluoxetine Hcl	65	22
Synthroid	Levothyroxine Sodium	64	15
Pantoprazole Sodium	Pantoprazole Sodium	61	18
Sertraline Hcl	Sertraline Hcl	59	17
Telmisartan	Telmisartan	57	23
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	56	suppressed
Ozempic	Semaglutide	55	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	55	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	53	23
Tamsulosin Hcl	Tamsulosin Hcl	53	16
Citalopram Hbr	Citalopram Hydrobromide	50	12
Valacyclovir	Valacyclovir Hcl	50	18
Zolpidem Tartrate	Zolpidem Tartrate	48	19
Ezetimibe	Ezetimibe	47	14
Alprazolam	Alprazolam	46	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	17
Irbesartan	Irbesartan	44	12
Metoprolol Tartrate	Metoprolol Tartrate	43	12
Celecoxib	Celecoxib	41	20
Estradiol	Estradiol	40	18
Pregabalin	Pregabalin	40	15
Fluticasone Propionate	Fluticasone Propionate	39	17
Mirtazapine	Mirtazapine	39	suppressed
Trulicity	Dulaglutide	39	suppressed
Montelukast Sodium	Montelukast Sodium	37	13
Potassium Chloride	Potassium Chloride	37	18
Jardiance	Empagliflozin	34	suppressed
Warfarin Sodium	Warfarin Sodium	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	14
Ropinirole Hcl	Ropinirole Hcl	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	11
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Azelastine Hcl	Azelastine Hcl	25	suppressed
Meloxicam	Meloxicam	25	13
Methocarbamol	Methocarbamol	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Allopurinol	Allopurinol	22	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Atenolol	Atenolol	21	suppressed
Lorazepam	Lorazepam	21	13
Premarin	Estrogens, Conjugated	21	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Prednisone	Prednisone	20	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Bumetanide	Bumetanide	19	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	14
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Methenamine Hippurate	Methenamine Hippurate	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Liothyronine Sodium	Liothyronine Sodium	17	suppressed
Ramipril	Ramipril	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	12
Valsartan	Valsartan	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Estradiol (Twice Weekly)	Estradiol	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	12
Clonazepam	Clonazepam	14	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Euthyrox	Levothyroxine Sodium	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Baclofen	Baclofen	12	suppressed
Diazepam	Diazepam	12	suppressed
Epinephrine	Epinephrine	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Progesterone	Progesterone, Micronized	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Nystatin	Nystatin	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error